Jiang YZ - Search Results

1

Emerging therapies in cancer metabolism.

Xiao Y, Yu TJ, Xu Y, Ding R, Wang YP, Jiang YZ, Shao ZM. Xiao Y, et al. Among authors: jiang yz. Cell Metab. 2023 Aug 8;35(8):1283-1303. doi: 10.1016/j.cmet.2023.07.006. Cell Metab. 2023. PMID: 37557070 Review.

2

The membrane complement regulatory protein CD59 promotes tumor growth and predicts poor prognosis in breast cancer.

Ouyang Q, Zhang L, Jiang Y, Ni X, Chen S, Ye F, Du Y, Huang L, Ding P, Wang N, Yang C, Huang T, Sun Y, Li S, Xia Y, Hu W, Luo R, Shao Z. Ouyang Q, et al. Int J Oncol. 2016 May;48(5):2015-24. doi: 10.3892/ijo.2016.3408. Epub 2016 Feb 24. Int J Oncol. 2016. PMID: 26935178

3

Transcriptome analysis of luminal breast cancer reveals a role for LOL in tumor progression and tamoxifen resistance.

Sun W, Xu X, Jiang Y, Jin X, Zhou P, Liu Y, Guo Y, Ma D, Zuo W, Huang S, He X, Shao Z. Sun W, et al. Int J Cancer. 2019 Aug 1;145(3):842-856. doi: 10.1002/ijc.32185. Epub 2019 Feb 19. Int J Cancer. 2019. PMID: 30720865 Free article.

4

Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity.

Huang Y, Wang H, Hao Y, Lin H, Dong M, Ye J, Song L, Wang Y, Li Q, Shan B, Jiang Y, Li H, Shao Z, Kroemer G, Zhang H, Bai L, Jin T, Wang C, Ma Y, Cai Y, Ding C, Liu S, Pan Y, Jiang W, Zhou R. Huang Y, et al. Nat Cell Biol. 2020 Jun;22(6):716-727. doi: 10.1038/s41556-020-0510-3. Epub 2020 May 4. Nat Cell Biol. 2020. PMID: 32367047

5

LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer.

Jin X, Ge LP, Li DQ, Shao ZM, Di GH, Xu XE, Jiang YZ. Jin X, et al. Among authors: jiang yz. Mol Cancer. 2020 May 11;19(1):87. doi: 10.1186/s12943-020-01210-9. Mol Cancer. 2020. PMID: 32393270 Free PMC article.

6

Tektin4 loss promotes triple-negative breast cancer metastasis through HDAC6-mediated tubulin deacetylation and increases sensitivity to HDAC6 inhibitor.

Ge LP, Jin X, Yang YS, Liu XY, Shao ZM, Di GH, Jiang YZ. Ge LP, et al. Among authors: jiang yz. Oncogene. 2021 Mar;40(12):2323-2334. doi: 10.1038/s41388-021-01655-2. Epub 2021 Mar 2. Oncogene. 2021. PMID: 33654196

7

BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer.

Wang X, Feng M, Xiao T, Guo B, Liu D, Liu C, Pei J, Liu Q, Xiao Y, Rosin-Arbesfeld R, Shi Y, Zhou Y, Yang M, Feng YX, Jiang Y, Shao Z, Yu K, Zhu D. Wang X, et al. Oncogene. 2021 Apr;40(16):2982-2997. doi: 10.1038/s41388-021-01756-y. Epub 2021 Mar 25. Oncogene. 2021. PMID: 33767438

8

Delayed initiation of radiation therapy is associated with inferior outcomes for breast cancer patients with hormone receptor-negative tumors after breast-conserving surgery.

Ma X, Chen J, Ma D, Jiang Y, Liu Z, Chen S, Zhang Y, Shen Y, Yu X, Yang Z, Li S, Mo M, Qian Y, Liu G, Wu J, Shao Z, Yu K, Di G. Ma X, et al. Gland Surg. 2021 Sep;10(9):2631-2643. doi: 10.21037/gs-20-717. Gland Surg. 2021. PMID: 34733713 Free PMC article.

9

Breast cancer screening and early diagnosis in Chinese women.

Ding R, Xiao Y, Mo M, Zheng Y, Jiang YZ, Shao ZM. Ding R, et al. Among authors: jiang yz. Cancer Biol Med. 2022 Apr 5;19(4):450-67. doi: 10.20892/j.issn.2095-3941.2021.0676. Online ahead of print. Cancer Biol Med. 2022. PMID: 35380032 Free PMC article. Review.

10

Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4/6 Inhibitors in Triple-Negative Breast Cancer.

Peng WT, Jin X, Xu XE, Yang YS, Ma D, Shao ZM, Jiang YZ. Peng WT, et al. Among authors: jiang yz. Cancer Res. 2023 May 15;83(10):1711-1724. doi: 10.1158/0008-5472.CAN-22-2143. Cancer Res. 2023. PMID: 37129951

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

431 results

Search Page